Adocia has announced the filing of a patent for its new long-acting peptide platform, AdoXLong, aimed at improving treatment options for diabetes and obesity.
The French biopharmaceutical company said the technology could extend the duration of action of acylated peptides to at least one month, with early results showing promise.
The patent’s initial application focuses on semaglutide, with Adocia reporting “promising in vitro and in vivo preliminary results indicating efficacy compatible with a once-monthly injection.” The platform is designed to work with a broad range of peptides including GLP-1, GIP, amylin and dual/triple agonists.
Adocia explained that the AdoXLong platform uses a biocompatible polymer chemically linked to peptides without altering their mechanisms of action. The resulting pharmaceutical products are low viscosity aqueous solutions suitable for subcutaneous injection using standard devices.
The company said the technology “would significantly improve long-term treatment persistence, while reducing the manufacturing capacity required per patient, thereby increasing the number of patients who can be treated.” If granted, the patent is expected to offer worldwide protection until 2046.
Olivier Soula, Chief Executive Officer and co-founder of Adocia, said: “We have leveraged the experience and insights gained from the AdoGel platform to adopt a different technical approach with AdoXLong, a promising platform targeting a patient experience as simple and comfortable as a weekly injection, while ensuring seamless integration into existing manufacturing processes.”
Adocia also provided an update on its BioChaperone platform, which stabilises and combines hormones for metabolic treatments. Soula explained: “Regarding BioChaperone, we remain confident in the value of the platform for obesity treatments, as evidenced by the two ongoing feasibility studies.” These studies are being conducted with two large pharmaceutical companies whose names remain undisclosed.
